With economic development coming to a halt across the globe, international business was restricted, requiring enterprises to carry out extensive COVID-19 testing drives within their companies periodically for uninterrupted business operations. As a result, the demand for rapid tests grew exponentially. Hangzhou AllTest Biotech Co., Ltd. successfully provided a large number of COVID-19 rapid tests to its clientele for the resumption of work and production activities, increasing their sales margins and reducing economic losses caused by the pandemic.
By implementing a strict and sturdy quality management system, the company ensures uncompromising quality across its product line. Effectively, such a team and well structured manufacturing competence enable Hangzhou AllTest Biotech Co., Ltd. to provide competitively priced solutions, additions to OEM/ODM services. Capable of delivering 500 million tests in a year, the company solidified its technological strengths with faster diagnostic testing systems.
Hangzhou AllTest Biotech Co., Ltd 's rapid tests showed exemplary performance characteristics, offering results within 5-15 minutes, all the while allowing for simplistic ease of operation without equipment training. It encourages easy specimen collection with oral fluid, nasal swab and nasopharyngeal swab (for COVID-19 antigen test) & Finger stick whole blood specimen (for COVID-19 antibody test). The tests can be further analyzed with LF Reader, Fluorescence Immunoassay Analyzer or PCR for the objective test. Collectively, these benefits validate Hangzhou AllTest Biotech Co., Ltd' s competencies in the POCT landscape, bolstered by its research, manufacturing, sales and marketing efforts. Despite the shortcomings of the pandemic, these skills enabled the company to increase publicity and awareness, enhance product quality, and help business partners expand the impact of product and sales performance.